Yonsei University: Ovarian Neoplasms trials

The registry lists 16 Ovarian Neoplasms studies with Yonsei University as lead sponsor. 5 are open to participants now and 0 have results posted.

Phase 2 8No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor TherapyRecruitingNCT07340164Phase 2
• Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis TechniquesRecruitingNCT07035587
• ACT-Based Nursing Intervention for Ovarian Cancer Patients: A Pilot StudyNot yet recruitingNCT06813001Not applicable
• A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)RecruitingNCT06023862Phase 2
• Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian CancerRecruitingNCT05444270Not applicable
• Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous CarcinomaStatus unknownNCT05665023Phase 2
• Detection of Circulating Tumor DNA Through Liquid Biopsies in Ovarian Cancer Patients and Evaluation of Prognostic and Predictive Values of Circulating Tumor DNA Assay.CompletedNCT05504174
• Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation.Status unknownNCT05458973
• Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP InhibitorStatus unknownNCT04734665Phase 2
• Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian CancerStatus unknownNCT04361370Phase 2
• A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)Status unknownNCT03899610Phase 2
• An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)Status unknownNCT03699449Phase 2
• Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian CancerStatus unknownNCT03618706Phase 2
• Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant ChemotherapyCompletedNCT03491033
• Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian CancerCompletedNCT03367182
• The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical TrialCompletedNCT02135523Not applicable